DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ambre James - 2 Brown - 2 ” - 1 Wegovy - 1 Catalent - 1 Eli Lilly - 1 LLY.N - 1 Susan Bain - 1
Top related locs:
U.S United States South Africa Ozempic Brussels Danish University of Southern California Wegovy
Top related orgs:
Novo Nordisk - 2 U.S . Food - 1 Drug Administration - 1 FDA - 1 University of Southern - 1 Novo executives - 1 Novo - 1 U.S - 1

Search resuls for: "Ambre James"


2 mentions found


☆ South Africa Runs Out of Insulin Pens as Global Supply Shifts to Weight-Loss Drugs
  + stars: | 2024-06-19 | by ( Stephanie Nolen | ) www.nytimes.com   time to read: +1 min
South Africa’s public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs that use a similar device for delivery. Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. Novo Nordisk’s drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens. A month’s supply of Ozempic in the United States costs about $1,000, far more than insulin.
Persons: ”, Ambre James, Brown Organizations: Novo Nordisk Locations: South Africa, U.S, Ozempic, United States
☆ Insight: Wegovy weight-loss injection factory plagued by sterile-safety failures
  + stars: | 2023-07-27 | by ( Maggie Fick | ) www.reuters.com   time to read: +10 min
Microbial contamination of drugs injected into the body, rather than swallowed, can be deadly, the people said - although the FDA inspectors didn't report any signs of this sort of contamination at the Brussels factory. In both visits, the FDA inspectors found Catalent staff had repeatedly failed to investigate why equipment was malfunctioning. BLINDSIDED BY BOOMING DEMANDWithin months of launching Wegovy, Novo Nordisk was overwhelmed by demand in America, and told shareholders that its initial supply would not keep pace. From December that year and throughout 2022, Novo repeatedly pushed out the timeline for when the supply constraints would end. In late December 2022, Novo announced all five dose strengths were available again in the United States.
Persons: Wegovy, Catalent, Eli Lilly, LLY.N, Susan Bain, Karsten Munk Knudsen, Ambre James, Brown, James, Knudsen didn't, Steven Lynn, Lynn, David Talmage, didn't, Novo, Maggie Fick, Vincent Flasseur, Michele Gershberg Organizations: U.S . Food, Drug Administration, Reuters, FDA, Novo Nordisk, University of Southern, Novo executives, Novo, U.S, Manufacturing, Parenteral Drug Association, Thomson Locations: U.S, Brussels, Danish, University of Southern California, Wegovy, Novo, America, United States
0 next >>
Total: 2